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Additional Sources Underlying 
Pathophysiology 
As with all diseases and illness 
there are signs and symptoms 
that medical personnel should be 
aware of and be able to recognize. 
According to the Malignant 
Hyperthermia Association of the 
United States (2015), Signs and 
symptoms for MH include: 
•  Increased heart rate 
•  Greatly increased body 
metabolism 
•  Muscle rigidity  
•  Fever that may exceed 110 
degrees F along with muscle 
breakdown, derangements 
of body chemicals and 
increased acid content in the 
blood. 
 
More severe complications: 
• Cardiac arrest 
• Brain damage 
• Internal bleeding or failure 
of other body systems 
 
Malignant hyperthermia crisis can 
mimic other complications and it 
should be addressed quickly or 
death could occur.  
According to the 
Malignant Hyperthermia 
Association of the United 
States (2015), “Malignant 
hyperthermia (MH) is a 
potentially fatal, inherited 
disorder usually associated 
with the administration of 
certain general anesthetics 
and/or the drug 
succinylcholine.” 
Malignant hyperthermia 
has been presented to me 
during hospital skills days 
over the past year due to 
the increased need for 
knowledge regarding this 
topic. I choose this topic 
because I find it interesting 
due to the fact that I could 
encounter this in the 
remainder of my days in 
the intensive care unit, but 
most importantly because 
I will be dealing with these 
drugs on a daily basis as a 
Nurse Anesthetist. 
Researching this topic in 
detail and presenting it 
will make me feel even 
more comfortable if one of 
my patients would 
experience the negative 
effects of anesthesia and 
go into malignant 
hyperthermia.  
      Those who are susceptible to 
malignant hyperthermia or experience 
MH have a mutation which causes the 
presence of abnormal proteins to build 
up in the muscle cells of their body. 
According the Kingler, Heiderich, Girard, 
Gravino, Heffron, Johannsen, & Lehman 
(2014), the mutation is found on the 
ryanodine receptor type 1 (RyR1).” 
Proteins that build up in the muscle cells 
is a normal occurrence in the human 
body, but these individuals when 
exposed to certain anesthetic agents or 
in some cases extreme heat or strenuous 
exercise, it causes an abnormal release 
of calcium from the sarcoplasmic 
reticulum in the muscle cells. The 
sarcoplasmic reticulum is where 
calcium is storage and when this occurs 
it results in a sustained muscle 
contraction which increases metabolism 
and heat production. Once the muscle 
cells have been contracted for a period 
of time they are eventually depleted of 
adenosine triphosphate (ATP), which is 
the source of cellular energy. The 
muscle cells will not be able to survive 
this and once they die the cells release 
large amounts of potassium into the 
bloodstream which causes 
hyperkalemia. The hyperkalemia can 
cause ventricular arrhythmias. 
Myoglobin, muscle pigment, is also 
released during this and can cause 
injury to the kidneys. (Malignant 
Hyperthermia Association, 2015).  
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Understanding the pathophysiology about MH can be beneficial for many 
reasons. As stated by Herlich (2013), it is crucial for medical personnel to make a 
more accurate diagnosis of perioperative fever or hyperthermia and subsequently 
choose the proper course of treatment. This would increase patient outcomes, 
decrease length of stays, etc. MH can have many poor outcomes if not treated 
promptly and accurately. Release of potassium causes hyperkalemia which can 
result in cardiac arrhythmias. Treating the high K will decrease the risk of cardiac 
arrhythmias and or death. The release of myoglobin can be toxic to the kidneys, so 
making sure to persevere kidney function with fluids would be beneficial. The 
patient’s body temperature must be controlled so the brain does not become injured. 
When comprehending what the body is going through during a MH crisis, those 
caring for the patient are able to treat the underlying causes more effectively.  
Significance of Pathophysiology 
Nurses must be attentive and recognize when a patient is deteriorating. Patients 
must be closely monitored for malignant hyperthermia as it can happen during 
surgery and the first hour after anesthesia, which is the most crucial time. It also, can 
occur if the anesthetic or succinylcholine is given in the emergency room or ICU for 
intubation. Nurses must recognize hemodynamic changes, rising carbon dioxide 
levels, increased temperature, muscle rigidity, and brownish colored urine. Once MH 
is suspected the nurse should notify the physician and use all resources to help assist 
with a patient whose body is going through an MH crisis. Orders will be given and a 
protocol should be followed. Dantrolene must be reconstituted and pushed. 
Tubes/drains should be flushed with chilled saline as well as chilled intravenous 
fluids should be started. The patient should be moved to the intensive care unit and 
monitored closely. The nurse caring for the patient should make sure the patient is 
safe and cared for in an appropriate and timely manner.  
Implications for Nursing Care 
Malignant 
hyperthermia can 
occur in a wide 
variety of areas and 
those working in 
areas where MH can 
occur they must be 
properly educated 
and prepared to 
recognize and act 
properly so poor 
patient outcomes 
don’t occur.  However, 
according to Cain, 
Riess, Gettrust, & 
Novalija (2014) “Many 
clinicians are 
unprepared to 
manage an MH crisis 
in the perioperative 
setting because it 
requires the use of 
low-frequency, high-
risk skills and 
procedures. 
Simulation is a 
recognized 
educational method 
for cumulative and 
integrative learning in 
a safe environment 
that resembles real-
life clinical scenarios” 
(pg1). As clinicians we 
must educate 
ourselves and use all 
our resources 
including the MH 
hotline who is ran by 
the Malignant 
Hyperthermia 
Association of the 
United States.  
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